US Stock MarketDetailed Quotes
BCDA BioCardia
- 2.330
- -0.040-1.69%
Close Oct 31 16:00 ET
8.16MMarket Cap-437P/E (TTM)
2.430High2.310Low44.20KVolume2.410Open2.370Pre Close104.11KTurnover1.68%Turnover RatioLossP/E (Static)3.50MShares23.25052wk High-4.16P/B6.13MFloat Cap1.95652wk Low--Dividend TTM2.63MShs Float129.000Historical High--Div YieldTTM5.06%Amplitude1.956Historical Low2.355Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
BioCardia Stock Forum
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
BioCardia has completed its Phase III CardiAMP HF trial, a randomized, double-blind, placebo-controlled study evaluating the CardiAMP Cell Therapy System for heart failure treatment. The trial enrolled 125 patients across 18 US hospitals, with 115 patients randomized 3:2 between treatment and control groups. The therapy, which received FDA Breakth...
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
BioCardia (Nasdaq: BCDA), a leader in cardiovascular and pulmonary disease therapeutics, has announced the pricing of an upsized $7.2 million public offering. The offering includes 2,400,000 shares of common stock (or pre-funded warrants) and warrants to purchase up to 2,400,000 shares at $3.00 per share and accompanying warrant. The warrants have a 5-year expirati...
No comment yet